| Bioactivity | Terodiline, an antispasmodic agent, blocks hERG current with the IC50 of 375 nM. Terodiline has both anticholinergic and calcium antagonist properties, and effectively reduces abnormal bladder contractions caused by detrusor instability. Terodiline can be used for the research of urinary incontinence[1][2]. |
| Target | mAChRCa2+ channel |
| In Vivo | Terodiline (80 mg/kg; S.C.) is equipotent in inhibiting intravesical bladder pressure and carbachol-induced salivary secretion (ID50= 24 and 35 mg/kg, respectively), and in increasing pupil diameter (ED50=59 mg/kg)[1]. Animal Model: |
| Name | Terodiline |
| CAS | 15793-40-5 |
| Formula | C20H27N |
| Molar Mass | 281.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ruth L Martin, et al. In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience. J Cardiovasc Pharmacol. 2006 Nov;48(5):199-206. [2]. H D Langtry, et al. Terodiline. A review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence. Drugs. 1990 Nov;40(5):748-61. |